Ohsu Knight Cancer Institute
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Phase 1
Recruiting
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: EchocardiographyBiological: ObinutuzumabOther: Questionnaire AdministrationBiological: Tafasitamab
- First Posted Date
- 2023-07-13
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT05943496
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas
Recruiting
- Conditions
- Glioma
- Interventions
- Other: Fludeoxyglucose F-18Other: Gadoterate MeglumineProcedure: Contrast-enhanced Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT05937776
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
Phase 4
Recruiting
- Conditions
- Castration Resistant Prostate CancerCastration Sensitive Prostate CancerProstate Adenocarcinoma
- Interventions
- Drug: PiflufolastatProcedure: PSMA PET/CT ScanProcedure: PSMA PET/MRI scanProcedure: Biospecimen CollectionOther: Electronic Health Record Review
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 80
- Registration Number
- NCT05919329
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Oxygen-Enhanced MRI for Generating Hypoxia Maps in Patients With Intracranial Tumors
Not Applicable
Recruiting
- Conditions
- Intracranial Neoplasm
- Interventions
- Procedure: Magnetic Resonance ImagingProcedure: Oxygen Therapy
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT05904704
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Use of Virtual Reality Goggles During Chemotherapy Infusion to Reduce Anxiety-Related Symptoms
Not Applicable
Completed
- Conditions
- Malignant Solid NeoplasmMalignant Breast NeoplasmMalignant Thoracic NeoplasmHematopoietic and Lymphoid System NeoplasmMalignant Head and Neck Neoplasm
- Interventions
- Other: Questionnaire AdministrationOther: Virtual Technology InterventionBehavioral: Telephone-Based Intervention
- First Posted Date
- 2023-03-31
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 50
- Registration Number
- NCT05793957
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Predicting the Impact of Treatment Toxicities on Health During Cancer ( PATTERN )
Active, not recruiting
- Conditions
- Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm
- Interventions
- Procedure: Assessment of Therapy ComplicationsOther: Electronic Health Record ReviewOther: Medical Device Usage and EvaluationOther: Survey Administration
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 200
- Registration Number
- NCT05790538
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 50
- Registration Number
- NCT05722925
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer
Phase 2
Recruiting
- Conditions
- Advanced Malignant Solid NeoplasmAdvanced Biliary Tract CarcinomaAdvanced Esophageal CarcinomaMetastatic Esophageal CarcinomaLocally Advanced Biliary Tract CarcinomaLocally Advanced Colorectal CarcinomaLocally Advanced Esophageal CarcinomaLocally Advanced Gastric CarcinomaMetastatic Colorectal Carcinoma (mCRC)Advanced Lung Carcinoma
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 66
- Registration Number
- NCT05705492
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Quantitative MRI Assessment of Breast Cancer Therapy Response
Recruiting
- Conditions
- Breast Cancer
- Interventions
- Procedure: Diffusion Weighted ImagingProcedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 135
- Registration Number
- NCT05704062
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸University of Washington, Seattle, Washington, United States
Enhancing Skin Cancer Early Detection and Treatment in Primary Care
Not Applicable
Completed
- Conditions
- Cutaneous Melanoma
- Interventions
- Behavioral: Training and Education
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 17
- Registration Number
- NCT05675709
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
© Copyright 2025. All Rights Reserved by MedPath